Repro Med Systems Stock Fundamentals
| KRMD Stock | USD 3.28 0.10 2.96% |
Fundamental analysis of Repro Med allows traders to better anticipate movements in Repro Med's stock price by examining its financial health and performance throughout various phases of its business cycle.
At present, Repro Med's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 22.4 M, whereas Operating Income is projected to grow to (6.1 M). Repro | Select Account or Indicator | Build AI portfolio with Repro Stock |
Repro Med Systems Company Return On Asset Analysis
Repro Med's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Repro Med Return On Asset | -0.13 |
Most of Repro Med's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Repro Med Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Repro Total Assets
Total Assets |
|
Based on the latest financial disclosure, Repro Med Systems has a Return On Asset of -0.1309. This is 98.5% lower than that of the Health Care Equipment & Supplies sector and 99.55% lower than that of the Health Care industry. The return on asset for all United States stocks is 6.5% lower than that of the firm.
Repro Med Systems Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Repro Med's current stock value. Our valuation model uses many indicators to compare Repro Med value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Repro Med competition to find correlations between indicators driving Repro Med's intrinsic value. More Info.Repro Med Systems is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Repro Med's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Repro Med by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Repro Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Repro Med's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Repro Med could also be used in its relative valuation, which is a method of valuing Repro Med by comparing valuation metrics of similar companies.Repro Med is currently under evaluation in return on asset category among its peers.
Repro Med ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Repro Med's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Repro Med's managers, analysts, and investors.Environmental | Governance | Social |
Repro Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | 155.57 M | ||||
| Shares Outstanding | 46.14 M | ||||
| Shares Owned By Insiders | 7.65 % | ||||
| Shares Owned By Institutions | 52.68 % | ||||
| Number Of Shares Shorted | 1.36 M | ||||
| Price To Earning | 11.56 X | ||||
| Price To Book | 9.80 X | ||||
| Price To Sales | 4.45 X | ||||
| Revenue | 33.65 M | ||||
| Gross Profit | 22.27 M | ||||
| EBITDA | (5.56 M) | ||||
| Net Income | (6.07 M) | ||||
| Cash And Equivalents | 18.27 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 3.99 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 5.40 X | ||||
| Book Value Per Share | 0.35 X | ||||
| Cash Flow From Operations | (319.72 K) | ||||
| Short Ratio | 3.00 X | ||||
| Earnings Per Share | (0.12) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 80 | ||||
| Beta | 0.47 | ||||
| Market Capitalization | 155.96 M | ||||
| Total Asset | 27.22 M | ||||
| Retained Earnings | (29.38 M) | ||||
| Working Capital | 11.93 M | ||||
| Current Asset | 2.54 M | ||||
| Current Liabilities | 516.46 K | ||||
| Net Asset | 27.22 M |
About Repro Med Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Repro Med Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repro Med using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repro Med Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2 M | 2.1 M | |
| Total Revenue | 33.6 M | 35.3 M | |
| Cost Of Revenue | 12.3 M | 12.9 M | |
| Stock Based Compensation To Revenue | 0.08 | 0.08 | |
| Research And Ddevelopement To Revenue | 0.16 | 0.16 | |
| Capex To Revenue | 0.04 | 0.03 | |
| Revenue Per Share | 0.73 | 0.77 | |
| Ebit Per Revenue | (0.19) | (0.18) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:Check out Repro Med Piotroski F Score and Repro Med Altman Z Score analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.175 | Return On Assets |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.